EUCTR2007-002846-38-IT进行中（未招募）不适用
A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE II/III STUDY TO EVALUATE THE SAFETY AND EFFICACY OF COMBRETASTATIN A-4 PHOSPHATE IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN COMPARISON WITH PACLITAXEL AND CARBOPLATIN AGAINST ANAPLASTIC THYROID CARCINOMA - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must have anaplastic thyroid carcinoma histologically or cytologically confirmed by a pathology review. Patients may have been refractory to or progressed during or after therapy, or relapsed within 6 months following initial combined modality therapy (usually including systemic chemotherapy and radiation) for regionally advanced disease. Where patients have received combined modality therapy for metastatic disease, systemic therapy is limited to one chemotherapy regimen that is clearly administered contiguously, (i.e., in an uninterrupted primary therapeutic approach). Patients who receive chemotherapy for metastatic disease after a combined modality approach are ineligible. In patients having received prior radiation, 4 weeks must have elapsed since radiation and disease must be present beyond radiation ports. A minimum of 3 weeks must have elapsed from the time a patient last received chemotherapy prior to the first dose of study drug (6 weeks for therapy known to be associated with delayed toxicity such as nitrosureas or mitomycin-C). Patients with bulky thyroid/neck masses and/or suspicion of airway obstruction must undergo screening (indirect and direct laryngoscopy) to ensure patency of the trachea/airway prior to study enrollment and treatment. Patients must be >/= 18 years of age. Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Score /= 12 weeks. Patients must have an adequate bone marrow reserve as evidenced by: absolute neutrophil count (ANC) > 1,500/µL and platelet count > 75,000/μL. Patients must have adequate renal function as evidenced by serum creatinine Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with tumors confined to the thyroid. Patients with an uncontrolled active infection. Clinically evident brain metastasis, including symptomatic involvement, evidence of cerebral edema by CT or MRI, radiographic evidence of progression of brain metastasis since definitive therapy, or continued requirement for corticosteroids. Patients who receive chemotherapy for metastatic disease after completion of a combined modality approach. Patients with history of malignancies other than ATC except patients with a curatively treated basal cell carcinoma of the skin, cervical intra-epithelial neoplasia, or localized prostate cancer with a current PSA of < 4.0 mg/dL or µg/L. (Patients with other curatively treated malignancies who have no evidence of metastatic disease will be considered after discussion with the Medical Monitor.) Patients with known hypersensitivity to CA4P, paclitaxel or carboplatin, or any of their components. Patients who are receiving concurrent investigational therapy or who have received investigational therapy for any indication within 28 days of the first scheduled day of dosing. (Investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication.) Patients with >/= Grade 3 peripheral neuropathy. Patients who are pregnant or lactating. Patients with a history of prior cerebrovascular event, including transient ischemic attack. Patients with uncontrolled hypertension defined as blood pressure > 150/100 mm Hg despite medication. Patients with symptomatic vascular disease (e.g. intermittent claudication) Patients with a history of unstable angina pectoris pattern, myocardial infarction (including non-Q wave MI) within the past 6 months, or NYHA Class III and IV congestive heart failure. Patients with a history of torsade de pointes. Patients with bradycardia (<60 b/m), heart block (excluding 1st degree block, being PR interval prolongation only), and congenital long QT syndrome. Patients with any ventricular arrhythmias or new ST segment elevation or depression or Q wave on ECG. Patients with ejection fractions less than normal (i.e. <45%). Patients with QTc prolongation > 450 ms. Patients requiring any drugs known to prolong the QTc interval, including antiarrhythmic medications. Patients with potassium concentrations below 4.0 mEq/dL and magnesium concentrations below 1.8 mg/dL despite being on an electrolyte supplement. Patients with any other intercurrent medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient?s ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results. Patients with a history of solid organ transplant or bone marrow transplant.
研究者
相似试验
进行中（未招募）
不适用
PROLONGED THERAPY WITH SUBCUTANEOUS BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE AFTER SALVAGE WITH BORTEZOMIB-BASED THERAPY.EUCTR2013-000432-10-ITDUTCH BELGIAN COOPERATIVE GROUP FOR HEMATOLOGY ONCOLOGY - HOVO154
进行中（未招募）
1 期
A Study of RO7247669 Alone or in Combination with Tiragolumab Versus Atezolizumab in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Bladder Cancer who are Ineligible for Platinum-Containing ChemotherapyPreviously Untreated Locally Advanced or Metastatic Urothelial Bladder CancerMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864EUCTR2022-002265-15-FRF. Hoffmann-La Roche Ltd240
进行中（未招募）
1 期
A Study of Tobemstomig Alone or in Combination with Tiragolumab Versus Atezolizumab in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer who are Ineligible for Platinum-Containing ChemotherapyEUCTR2022-002265-15-DEF. Hoffmann-La Roche Ltd240
进行中（未招募）
1 期
A Study of Tobemstomig Alone or in Combination with Tiragolumab Versus Atezolizumab in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer who are Ineligible for Platinum-Containing ChemotherapyPreviously Untreated Locally Advanced or Metastatic Urothelial CancerMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-002265-15-DKF. Hoffmann-La Roche Ltd240
进行中（未招募）
1 期
A randomized study of the safety and efficacy of a novel drug, DNIB0600A, compared to chemotherapy when given intravenously to patients with ovarian cancer.Platinum Resistant Ovarian CancerMedDRA version: 16.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005776-34-GBGenentech, Inc.92